Positron Emission Tomography in Breast Cancer.
Positron Emission Tomography in Breast Cancer.
复制标题
DOI：
10.3390/diagnostics5010061
复制
发表时间：
2015-03-16
期刊：
影响因子：
--
通讯作者：
Cózar-Santiago Mdel P
中科院分区：
文献类型：
--
作者：
Vercher-Conejero JL;Pelegrí-Martinez L;Lopez-Aznar D;Cózar-Santiago Mdel P
FDG-PET/CT在肿瘤疾病的诊断算法中逐渐得到加强。在其中许多方面，PET/CT 已被证明在疾病的不同阶段都很有用：诊断、分期或重新分期、治疗反应评估和复发。与 CT、MRI、骨扫描、乳房 X 线摄影或超声波相比，这种成像方式的一些优点是基于其强大的诊断能力，因为根据所使用的放射性药物，它反映了通常在形态变化之前发生的代谢变化，因此使我们能够进行分期诊断。此外，这项技术的另一个优点是它允许我们评估整个身体，因此对于检测远处的疾病非常有用。对于乳腺癌，FDG-PET/CT 已被证明在怀疑复发或评估治疗反应时非常重要。通过开发专为乳腺成像设计的新型探测器和设备，以及开发用于研究乳腺癌不同生物过程的更具体的放射性药物，PET 设备的技术进步不仅将在疾病的早期诊断方面取得进展，而且还将在为乳腺癌患者提供个性化治疗方面取得进展。
Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer.